California Institute for Quantitative Biosciences

Global Smart Pills Market Report 2022-2027: Growing Preference for Non-Invasive Procedures Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Health Technology, Pharmaceutical, Health, MRI, Brain, Diagnosis, Magnetic spin vortex disc, Degenerative disease, Esophagus, Hospital, Temperature, Stomach, Silicon, Research, Field line, Health, California Institute for Quantitative Biosciences, PH, Gastrointestinal tract, Patient, Blood, Endoscopy, Pressure, Google Images, Magnetic resonance imaging, Growth, Capsule endoscopy, Birth control, Medical imaging, California Institute of Technology, Technology

The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The growing preference for non-invasive procedures is driving the smart pills market.
  • Therefore, non-invasive procedures are driving the smart pills market during the period.
  • The high cost of smart pills associated with technological advancement will act as a restraint to the market growth.

Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric Health

Retrieved on: 
Wednesday, July 13, 2022
Movement, Genius, Biophysical environment, Discover (magazine), Anxiety, Communication, Student, Program, Education, CSO, LOS, California Institute for Quantitative Biosciences, Probiotic, Hope, Therapy, Cognition, Luis, CEO, Neurodegeneration, Emotion, Hypothalamus, Brain, MacArthur Foundation, Depression, Autism, Alzheimer's disease, Biodiversity, Parkinson's disease, Medicine, Division, J&J, Mental health, Skin, Reproductive health, Central nervous system, Human, Disorder, Pediatrics, Research, Board, CNS, Health, Industry, Behavior, Drug development, Social, Seed, Dietary supplement, Birth control, Medical imaging, Pharmaceutical industry, Nature, Axial, Science, California Institute of Technology, Microbiology, Biology

LOS ANGELES and BOSTON, July 13, 2022 /PRNewswire/ -- Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like anxiety, depression and stress response. The program builds on the work of Axial co-founder and Board Member and Seed Health Board Member Dr. Sarkis Mazmanian, whose California Institute of Technology (Caltech) lab first discovered the critical contributions of intestinal microbes and microbial metabolites in neuropsychiatric conditions. With joint expertise across discovery, mechanistic validation, microbial fermentation, scale-up, clinical research and commercialization, the program is uniquely positioned to transform the current paradigm of treatment in mental health.

Key Points: 
  • Dr. Mazmanian's lab was the first to discover that molecular signals from gut bacteria can profoundly influence anxiety behavior.
  • The collaboration between Seed Health and Axial Therapeutics will translate this breakthrough research into novel probiotics and living medicines for a range of cognitive and neuropsychiatric outcomes."
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders.

Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric Health

Retrieved on: 
Wednesday, July 13, 2022
Movement, Genius, Biophysical environment, Discover (magazine), Anxiety, Communication, Student, Program, Education, CSO, LOS, California Institute for Quantitative Biosciences, Probiotic, Hope, Therapy, Cognition, Luis, CEO, Neurodegeneration, Emotion, Hypothalamus, Brain, MacArthur Foundation, Depression, Autism, Alzheimer's disease, Biodiversity, Parkinson's disease, Medicine, Division, J&J, Mental health, Skin, Reproductive health, Central nervous system, Human, Disorder, Pediatrics, Research, Board, CNS, Health, Industry, Behavior, Drug development, Social, Seed, Dietary supplement, Birth control, Medical imaging, Pharmaceutical industry, Nature, Axial, Science, California Institute of Technology, Microbiology, Biology

LOS ANGELES and BOSTON, July 13, 2022 /PRNewswire/ -- Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like anxiety, depression and stress response. The program builds on the work of Axial co-founder and Board Member and Seed Health Board Member Dr. Sarkis Mazmanian, whose California Institute of Technology (Caltech) lab first discovered the critical contributions of intestinal microbes and microbial metabolites in neuropsychiatric conditions. With joint expertise across discovery, mechanistic validation, microbial fermentation, scale-up, clinical research and commercialization, the program is uniquely positioned to transform the current paradigm of treatment in mental health.

Key Points: 
  • Dr. Mazmanian's lab was the first to discover that molecular signals from gut bacteria can profoundly influence anxiety behavior.
  • The collaboration between Seed Health and Axial Therapeutics will translate this breakthrough research into novel probiotics and living medicines for a range of cognitive and neuropsychiatric outcomes."
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022
Diamond, Meiosis, Mouse, Science, NaVorro Bowman, SKI, Biology, Research, Sexual fluidity, Gay pride, APA, Berkeley, Analytics, AIDS, Student, Identity, Industry, KOL, Publication, Domestic Partnership Benefits and Obligations Act, National Science Foundation, Developmental Biology (journal), Occidental College, California Institute of Technology, Faculty, Doctor of Philosophy, Imperial College London, LGBTQ, LGBTQIA, Queer, Internet, California Institute for Quantitative Biosciences, Time, Chemistry, Twitter, News, Lists of people executed in the United States, NSF, Conference, MSK, Management, Technology

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022
Diamond, Meiosis, Mouse, Science, NaVorro Bowman, SKI, Biology, Research, Sexual fluidity, Gay pride, APA, Berkeley, Analytics, AIDS, Student, Identity, Industry, KOL, Publication, Domestic Partnership Benefits and Obligations Act, National Science Foundation, Developmental Biology (journal), Occidental College, California Institute of Technology, Faculty, Doctor of Philosophy, Imperial College London, LGBTQ, LGBTQIA, Queer, Internet, California Institute for Quantitative Biosciences, Time, Chemistry, Twitter, News, Lists of people executed in the United States, NSF, Conference, MSK, Management, Technology

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.

#PrideMonth: 8 LGBTQIA Key Opinion Leaders (KOLs) Making Big International Impact

Retrieved on: 
Wednesday, June 29, 2022
Diamond, Meiosis, Mouse, Science, NaVorro Bowman, SKI, Biology, Research, Sexual fluidity, Gay pride, APA, Berkeley, Analytics, AIDS, Student, Identity, Industry, KOL, Publication, Domestic Partnership Benefits and Obligations Act, National Science Foundation, Developmental Biology (journal), Occidental College, California Institute of Technology, Faculty, Doctor of Philosophy, Imperial College London, LGBTQ, LGBTQIA, Queer, Internet, California Institute for Quantitative Biosciences, Time, Chemistry, Twitter, News, Lists of people executed in the United States, NSF, Conference, MSK, Management, Technology

And who better to look up to than key opinion leaders (KOLs) who are making a big impact.

Key Points: 
  • And who better to look up to than key opinion leaders (KOLs) who are making a big impact.
  • Here is a list compiled by the Analytics firm KOLs (Key Opinion Leaders) of the top 8 LGBTQIA+ KOLs you should know about.
  • Diamond is one of the key opinion leaders (KOLs) attending this year's LGBTQ Health Conference.
  • As an expert in cofilin loss, Stefanie Elisabeth Windner is quickly becoming one of the top Key Opinion Leaders in this field.

Greentown Labs Appoints Barbara Burger to its Board of Directors

Retrieved on: 
Thursday, June 16, 2022
Lubricant, Berkeley, Trustee, Solution, Climate change, Central Waqf Council, California Institute for Quantitative Biosciences, Strategic Advisory Board for Intellectual Property Policy, Technology, Innovation, Chevron, Woman, Chemistry, Oil, Knowledge, Leadership, City, Student, Science, LinkedIn, Massachusetts Institute of Technology, Director, Growth, Board of directors, National Renewable Energy Laboratory, Environmental science, Ecosystem, University, General counsel, Partnership, Twitter, Software, Board, Chevron Corporation, Microsoft, Face, Management, Renewable energy, California Institute of Technology, Facebook

SOMERVILLE, Mass. and HOUSTON, June 16, 2022 /PRNewswire/ -- Greentown Labs, the largest climatetech startup incubator in North America, today announced that it has appointed Barbara J. Burger, Ph.D., former Vice President of Innovation and President of Chevron Technology Ventures, to its board of directors.

Key Points: 
  • Dr. Burger has been a long-time, transformative supporter of Greentown Labs and the opening of its Houston incubator.
  • While at Chevrona Greentown Labs partner since 2013she spearheaded the corporate's partnership with Greentown, and Chevron became the first Founding Partner of Greentown Houston , which opened in 2021.
  • "I am honored and excited to join the Greentown Labs Board of Directors," said Dr. Burger.
  • Dawn James , Director of U.S. Sustainability Strategy and Environmental Science at Microsoft
    "I am thrilled to welcome Barbara to our already outstanding Board of Directors at Greentown Labs," said Barton.

Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease

Retrieved on: 
Monday, June 13, 2022
Woman, Hyperthyroidism, TPG, Eyelid, Degenerative disease, Temple University, Chemistry, Biology, Research, Graves' disease, Drug discovery, Food, Linsitinib, Health care, Science, Astellas Pharma, Inflammation, Pain, University, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, California Institute of Technology, Arak University of Medical Sciences, Therapy, FDA, Vaccine, Massachusetts Institute of Technology, Patient, ANN, Cros, Director, Immune system, University of Michigan Institute for Social Research, Quality of life, Novartis, Bellevue University, Prevalence, Clinical trial, California Institute for Quantitative Biosciences, Board, Drug development, Health, Chemical engineering, Graves' ophthalmopathy, Pharmaceutical industry, Healthcare, TED, Celgene, Pharmacy, Technology

ANN ARBOR, Mich., June 13, 2022 /PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the official launch of the company with a $35M Series A financing led by TPG's The Rise Fund. The funds will support a Phase 2b clinical trial evaluating the company's investigational drug, linsitinib, for the treatment of TED.

Key Points: 
  • TED is a debilitating autoimmune disease that affects about 20,000 people in the U.S. per year and has a similar prevalence in Europe.
  • As the disease progresses it can lead to pain, eye bulging, double vision, and a profound reduction in quality of life.
  • Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED).
  • Linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED.

Numinus completes acquisition of Novamind and announces executive appointments

Retrieved on: 
Saturday, June 11, 2022
Mission statement, Psychotherapy, Time, Company, Lists of diseases, Trauma, Pain, Toronto Stock Exchange, Medical director, Certification, Psycho-oncology, Psychedelic therapy, University, RSU, Cancer, CSE, Canadian Securities Exchange, Depression, Legislation, Transaction, CEO, Partnership, Center, Par value, Multidisciplinary Association for Psychedelic Studies, MD, Psychiatry, MAPS, Indian stock exchange, SEDAR, Experiential learning, Anxiety, Supreme Court of British Columbia, Patient, Alternative, Acquisition, TSX, Ketamine, California Institute for Quantitative Biosciences, Research, News, FDA, Growth, Clinic, Brigham Young University, Risk, Nursing care plan, Cost-exchange ratio, Opioid use disorder, Medicine, Pharmaceutical industry, Security (finance), Esketamine, List of cosmic entities in Marvel Comics, BC

This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.

Key Points: 
  • This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues.
  • Numinus is also pleased to announce the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind.
  • As approved by shareholders on June 8, 2022, Numinus has issued 43,474,659 common shares to the former shareholders and RSU holders of Novamind, as consideration for the acquisition representing 0.84 of one (the "Exchange Ratio") Numinus common share per each Novamind share and Novamind restricted share unit (RSU).
  • Given securities processing times, these Numinus shares should settle in Novamind investor accounts by June 16, 2022.

Morrison Foerster Adds Experienced Technology Transactions and Life Sciences Attorney Matthew Ferry as Partner in San Diego

Retrieved on: 
Tuesday, June 7, 2022
Woman, Leadership, UCLA School of Nursing, Lawyer, Veteran, Journal, Biotechnology, International Conference on Neutrino Physics and Astrophysics, IP, Patent, Berkeley, Morrison & Foerster, Private law, Environment, List of life sciences, Investment, University, The American Lawyer, Chambers, Growth, Hygiene, Minnesota Journal of Law, Science & Technology, Civil and political rights, Ferry, SAN, California Institute for Quantitative Biosciences, Industry, Small business, Culture, Health, Financial technology, Acıbadem Healthcare Group, UCLA School of Law, Fortune 500, Color, Pharmaceutical industry, Law, Physics, Technology

SAN DIEGO, June 7, 2022 /PRNewswire-PRWeb/ -- Morrison Foerster, a leading global law firm, is pleased to announce the arrival of Matthew Ferry as a partner in the firm's Life Sciences Transactions + Licensing and Technology Transactions Groups, based in San Diego. Ferry brings more than a decade of combined technology transactions, life sciences transactions, and licensing experience to Morrison Foerster.

Key Points: 
  • SAN DIEGO, June 7, 2022 /PRNewswire-PRWeb/ -- Morrison Foerster , a leading global law firm, is pleased to announce the arrival of Matthew Ferry as a partner in the firm's Life Sciences Transactions + Licensing and Technology Transactions Groups, based in San Diego.
  • Ferry brings more than a decade of combined technology transactions, life sciences transactions, and licensing experience to Morrison Foerster.
  • Ferry joins Morrison Foerster from another leading international law firm, where he advised clients on life sciences, pharmaceutical, strategic IP, technology, data, and information-related transactions.
  • "Morrison Foerster is a well-known global life sciences and technology leader with exceptional life sciences and transactional capabilities and highly skilled attorneys," said Ferry.